- Home
- LFMD vs ETON Comparison
LFMD vs ETON Comparison
Compare LFMD & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFMD
- ETON
- Stock Information
- Founded
- LFMD 1994
- ETON 2017
- Country
- LFMD United States
- ETON United States
- Employees
- LFMD N/A
- ETON N/A
- Industry
- LFMD Medical/Nursing Services
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- LFMD Health Care
- ETON Health Care
- Exchange
- LFMD Nasdaq
- ETON Nasdaq
- Market Cap
- LFMD N/A
- ETON 428.5M
- IPO Year
- LFMD N/A
- ETON 2018
- Fundamental
- Price
- LFMD $8.16
- ETON $17.33
- Analyst Decision
- LFMD Strong Buy
- ETON Strong Buy
- Analyst Count
- LFMD 6
- ETON 3
- Target Price
- LFMD $11.17
- ETON $27.67
- AVG Volume (30 Days)
- LFMD 2.1M
- ETON 221.4K
- Earning Date
- LFMD 05-06-2025
- ETON 05-13-2025
- Dividend Yield
- LFMD N/A
- ETON N/A
- EPS Growth
- LFMD N/A
- ETON N/A
- EPS
- LFMD N/A
- ETON N/A
- Revenue
- LFMD $234,007,330.00
- ETON $39,011,000.00
- Revenue This Year
- LFMD $29.08
- ETON $92.33
- Revenue Next Year
- LFMD $18.81
- ETON $52.62
- P/E Ratio
- LFMD N/A
- ETON N/A
- Revenue Growth
- LFMD 43.07
- ETON 23.29
- 52 Week Low
- LFMD $3.99
- ETON $3.18
- 52 Week High
- LFMD $10.70
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- LFMD 68.73
- ETON 68.29
- Support Level
- LFMD $7.11
- ETON $16.43
- Resistance Level
- LFMD $8.54
- ETON $17.49
- Average True Range (ATR)
- LFMD 0.57
- ETON 0.88
- MACD
- LFMD 0.20
- ETON 0.19
- Stochastic Oscillator
- LFMD 84.99
- ETON 92.78
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.